Virios Therapeutics (VIRI) Reports Q1 Loss of $0.37

Virios Therapeutics (NASDAQ: VIRI) reported Q1 EPS of ($0.37), versus ($0.10) reported last year.

“Our team has made significant operational progress to ensure the commencement of our landmark Phase 2b fibromyalgia clinical trial, referred to as FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1), with top line results projected in mid-2022,” stated Greg Duncan, Chairman and Chief Executive Officer. “We are pleased to see the research community’s growing excitement about IMC-1 as a potential treatment for fibromyalgia, as evidenced by the rapid sign up of more than 40 clinical trial sites and the acceptance of new analyses from our Phase 2a study results to be presented in June at two major medical meetings, the European Congress of Rheumatology (EULAR), and the International Association for the Study of Pain (IASP) World Congress.”

For earnings history and earnings-related data on Virios Therapeutics (VIRI) click here.

You May Also Be Interested In

• Occidental Petroleum releases Q2 2026 earnings considerations
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
• Park Aerospace names John Jamieson as senior VP and general manager